Obstructive Sleep Apnea Hypopnea Syndrome: a Proinflammatory Disorder
Hideo Wakayama,Toshiaki Shiomi
DOI: https://doi.org/10.1097/00029330-200709010-00001
IF: 6.133
2007-01-01
Chinese Medical Journal
Abstract:Obstructive sleep apnea hypopnea syndrome (OSAHS) is a rather frequent disorder affecting 2%-4% of the general population. Large cohort studies have confirmed that obstructive sleep apnea (OSA) is an independent risk factor for cardiovascular disease (CVD), including myocardial infarction, hypertension, stroke and so on. For example, Sleep Heart Health Study (SHHS) demonstrated that the prevalence of CVD (including myocardial infarction, angina, coronary revascularization, heart failure, stroke) was 1.42 times greater in patients with OSA (apnea/hypopnea index (AHI)>11 events/hour) than in those without OSA.1 However, the exact mechanisms linking sleep apnea to cardiovascular morbidity remain unclear. Two studies2,3 published in this issue of the Journal measured a series of subclinical inflammatory factors in patients with OSA, and added new evidence linking sleep apnea to cardiovascular morbidity. Obstructive sleep apnea is usually associated with “Syndrome X” (metabolic syndrome), which included insulin resistance (IR) and diabetes, dyslipidemia, hypertension, and obesity. In recent years snoring and OSA have been proposed to add to “Syndrome X” and the new entity was called “Syndrome Z”,4 due to the fact that more and more evidences suggest that OSA itself may be a primary feature inducing or aggravating these series of vascular and metabolic disturbances. Impairment of insulin and glucose homeostasis, which is considered as the key of metabolic syndrome has been confirmed after adjustment to potential confounders such as age, sex and body mass index (BMI) in patients with OSA. In the large-scale clinical investigation of SHHS, the odds ratio for fasting glucose intolerance was 1.7 for mild and 1.46 for severe OSA. It was estimated that each additional apneic episode increased plasma insulin and the homeostasis model assessment (HOMA)-index by 0.5%, and each 4% drop in SaO2 represented an odds ratio of 1.99 for glucose intolerance. Sleep deprivation caused by frequently interrupted sleep and nocturnal microarousals also lead to IR. Furthermore, a significant improvement in insulin sensitivity has been achieved by continuous positive airway pressure (CPAP) therapy.5 This effect was also maintained after 3 months’ CPAP therapy. The above data suggest that OSA can be causal to the metabolic disturbances. The paper by Zhang et al2 focused on the therapeutic effect of CPAP on serum adiponectin level. Adiponectin is an adipose tissue-specific collagen-like factor, which modulates the endothelial inflammatory response in vitro. It is associated with lipid and glucose metabolism, and insulin resistance. Clinically its concentration is decreased in patients with coronary artery disease, obesity and type-2 diabetes. Treatment of diabetic animals with adiponectin markedly improved insulin sensitivity. Adiponectin, like other adipocyte-derived biologically active peptides such as leptin and resistin, is one of the key molecules in the metabolic syndrome. The finding of adiponectin increase independent of BMI change following two weeks’ CPAP treatment by Zhang et al,2 together with the data of reduced pre-treatment adiponectin level by the same group6 suggest that adiponectin may be a potential factor involved in the development of prediabetes and diabetes in OSA. However, the finding of unchanged blood glucose and HOMA index at all time points during the two-week interval is somewhat unexpected and counterintuitive because increase of adiponectin level would be expected to be associated with improvement of insulin sensitivity. The mechanisms of this “paradoxical” finding are not known. Others also reported that OSA is associated with reduced levels of adiponectin independently of insulin-resistance. The smaller patients number, the bigger variation of HOMA in this group of patients and lack of control make the interpretation of the results difficult. Further study with a more sensitive measurement of insulin sensitivity using hyperinsulinemic euglycemic clamp may be needed. Further improvement after CPAP treatment longer than 2 weeks is also possible. Another outcome in this study was blood pressure. With the remarkable increase of adiponectin under 2 weeks CPAP therapy, both mean and diastolic blood pressure decreased significantly. Previous reports have demonstrated that male patients with hypoadiponectinemia had a significant 2-fold increase in CAD prevalence, independent of well-known CAD risk factors. Another large sample study found that hypoadiponectinemia related to the T/C genotype of the I164T polymorphism is a marker for predisposition to hypertension in men. Both studies did not report the occurrence of OSA in their patient population, because sleep apnea is very common in patients with CAD, and it is conceivable that OSA may influence adiponectin levels in these studies. The parallel change of blood pressure and adiponectin leads the author to conclude that hypoadiponectinemia might be involved in the pathogenesis of OSA related hypertension. However, further study needs to be carried out to establish whether hypoadiponectinemia can be causal to the elevated blood pressure in patients with OSA. Many epidemiologic studies show positive associations between elevated C-reactive protein (CRP) levels and incident CVD. National guidelines by American Heart Association regarding the clinical utility of high sensitivity C-reactive protein (hsCRP) in primary and secondary prevention settings have been recently issued. In a group of OSA patients free of prevalent medical conditions including hypertension, diabetes mellitus, and cardiovascular disease, a strong association was found between degrees of OSA and serum levels of CRP independent of obesity in a recent published study.7 The elevation of CRP can be reversed following CPAP treatment. The paper by Ye et al3 reported elevation of CRP and matrix metalloproteinase-9 (MMP-9), which were both correlated with the severity of OSA, in a group of pre-treatment OSA patients. This is consistent with the results in most of the published studies. One of the new findings in this study was the positive correlation of circulation MMP-9 and CRP levels in the untreated OSA patients. CRP-level is an epiphenomenon of subclinical inflammatory activity, but not a directly acting factor. Presumably, CRP may serve as an atherogenesis factor mediated by pathway of increase of MMP-9 level, which results in degradation of the fibrous cap, plaque instability, and plaque rupture. Certainly, this needs to be further clarified at the cellular/molecular biological level, one feasible approach is to use its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1) to block the MMP-9 pathway, and observe the effect on CRP function. Taken together, the data of Zhang et al2 and Ye et al3 may reflect another aspect of the risk profile of CVD. Obesity, metabolic syndrome and sleep apnea have all been recognized as pro-inflammatory states.8,9 The mechanism by which OSAHS is associated with hypertension and contributes to IR and dyslipidaemia is not fully understood, but activation of the inflammatory cascade seems to be the common pathway for all of these disease states. These studies may also lay important groundwork for the pharmacological intervention to prevent and/or treat the cardiovascular complications of OSA. The use of anti-inflammatory agents may be of special value in those patients who have poor compliance or refuse to use CPAP. However, the interaction of these parameters, their individual degree of contribution to athrosclerosis and their clinical revelance still has to be established.